Category Archives: Tms

#Preview Product1ZINUS 9 Inch Metal Smart Box Spring / Mattress Foundation / Strong Metal Frame / Easy Assembly,... Check Price Now 2TMS Kayak Canoe Jon Boat Carrier Dolly Trailer Tote Trolleyw/Free Cell Phone Bag Check Price Now 3Bed Canopy with LED Star Lights, Mosquito Net for Bed with 18 Colors Changing String Lights Remote... Check Price Now 4Luxury Mosquito Net Bed Canopy, Ultra Large: for Single To King Size, Quick Easy Installation,... Check Price Now 5Stars Bed Canopy Glow in The Dark, Eimilaly Bed Canopy for Girls Mosquito Net, Princess Canopy for... Check Price Now 6TMS J-Bar Rack HD Kayak Carrier Canoe Boat Surf Ski Roof Top Mounted on Car SUV Crossbar Check Price Now 7Curtain Lights for Decorations, 10 Ft Connectable String Lights with 8 Twinkle Modes Led Fairy... Check Price Now 8 Twinkle Star Bed Canopy for Single to King Size Beds (White) Check Price Now 9Kertnic Decor Canopy for Kids Bed, Soft Smooth Playing Tent Canopy Girls Room Decoration Princess... Check Price Now 10 Mosquito NET for Bed Canopy, Four Corner Post Curtains Bed Canopy Elegant Mosquito Net Set, Stick... Check Price Now 1. Twinkle Star 4 Corner Post Bed Canopy for Full/Queen/King Size Bed (Elegant Black)

Tech specialist. Social media guru. Evil problem solver. Total writer. Web enthusiast. Internet nerd. Passionate gamer. Twitter buff.

Continued here:

Top 10 Best Tms Bed Canopies 2021 Bestgamingpro - Best gaming pro

HOUSTON, Aug. 20, 2021 /PRNewswire/ -- Sentai announced today that it acquired LUPIN THE 3rd PART 6, the next thrilling adventure in the saga of globetrotting thief, Lupin III. The latest installment commemorates the 50th anniversary of this incredibly influential franchise. Sentai will distribute the series to audiences in North America, Australia, New Zealand, Scandinavia, and all Nordic Countries.

Gentleman thief Lupin III is back and ready for his next caper unless legendary sleuth, Sherlock Holmes, has anything to say about it! When Holmes' longtime partner, Dr. Watson, is murdered, none other than Lupin tops the suspects list. With Holmes fast closing in, Lupin must prove his innocence and bring a shadowy organization called The Raven to heel if he wants to live to steal another day.

Produced by TMS Entertainment (Dr. Stone) and based on the original work of Monkey Punch, LUPIN THE 3rd PART 6 is directed by Eiji Suganuma (Mashiroiro Symphony: The Color of Lovers) with music from longtime series music composer Yuji Ohno and series composition by Takahiro Okura (LUPIN THE 3rd PART 5). Hirotaka Marufuji provides the series' character design (LUPIN THE 3rd: Goodbye Partner).

The escapades of Lupin III have thrilled audiences for decades, with entries in the franchise spanning everything from manga and anime series to feature films and live action adaptations. To celebrate this beloved franchise's 50th anniversary, TMS Entertainment is making 2021 the "Year of Lupin," bringing audiences a brand-new Lupin adventure along with exciting events, new theatrical and home video releases, and more.

Sentai will stream LUPIN THE 3rd PART 6 in association with select digital outlets with a home video release to follow.

For more information on LUPIN THE 3rd PART 6, visit http://lupinpart6.com/.

For Sentai's latest announcements regarding this and other great titles, be sure to like us on Facebookand follow us on Twitter.

For TMS Entertainment's latest announcements regarding LUPIN THE 3rd and other titles, be sure to like us on Facebookand follow us on Twitter.

About SentaiA Cool Japan Fund portfolio company, Sentai is a leading global supplier of anime and official anime merchandise, distributing and curating one of the industry's most diverse libraries of top trending and classic titles. Sentai offers thousands of hours of content across both traditional and digital platforms and is dedicated to bringing captivating stories and iconic characters directly from Japan. With hit series that include MADE IN ABYSS, Food Wars!, Princess Tutu and Parasyte -the maxim-, Sentai's catalog continues to grow with new favorites like Bloom Into You, Revue Starlight and O Maidens in Your Savage Season, as well as classic anime series such as Legend of the Galactic Heroes and The Big O. For more information, visit http://www.sentai.com.

About TMS Entertainment USA, Inc.TMS Entertainment USA, Inc. is a subsidiary of TMS Entertainment Co., Ltd. (better known as TMS), one of the largest anime studios in Japan. With strong focus on anime production, licensing, and distribution businesses, TMS boasts a library of over 12,000 episodes across a total of 420 titles that include much-loved anime titles such as "LUPIN THE 3rd," "Dr. STONE," and "MEGALOBOX." For more information, visit http://www.tmsanime.com

Media Contact:Tom Helberg(832) 271-6662[emailprotected]

SOURCE Sentai Holdings, LLC

http://www.sentai.com

Read the original post:

Sentai Nabs LUPIN THE 3rd PART 6 Anime Series - PRNewswire

According to SentaiFilmworks, the legendary thief will clash with a legendary detective. Sherlock Holmes is after Lupin following the murder of his longtime partner Dr. Watson. Lupin is the prime suspect in the murder and has to prove his innocence. He also has to deal with an evil organization called The Raven.As the TMS site notes, the key visual of "LupinIII: Part VI" is supposed to depict Lupin's complexity.The image showcases the head of a smirking Lupin, but the sides of his face differ. While the right side of his face looks like the normal easygoing protagonist we're used to seeing, the left side, covered in shadows with a piercing red eye, makes him look more villainous. The image may symbolize how Holmes sees the thief in the series versus how others see him, which makes sense given that Lupin is suspected of murder.

Based on the trailer, the tone could be more serious for this anime. While most of the TV versions of "Lupin III" are lighter in tone, other works like "Lupin III: The Woman Called Fujiko Mine" and the trilogy of films directed by Takeshi Koike are much darker. This is more in line with Monkey Punch's original manga, which was heavier on sex and violence and had more black humor compared to some of the TV series' more zany moments. The trailer definitely presents a somber air for our favorite gentleman thief, and we're excited to tune in this fall.

Read more from the original source:

Lupin III: Part VI Release Date, Cast And Plot - What We Know So Far - Looper

TMS technology was developed in 1985 and has been gaining clinical interest since then. Two-thirds of TMS patients experienced either full remission of their depression symptoms or noticeable improvements.1 An out-patient procedure, TMS does not have serious side effects.

Mechanism of Action

Approved by the US Food and Drug Administration in 2008, TMS uses an alternating current passed through a metal coil placed against the scalp to generate rapidly alternating magnetic fields. These pass through the skull nearly unimpeded and induce electric currents that depolarize neurons in a focal area of the surface cortex.

The magnetic field generated by TMS is comparable to that of a standard magnetic resonance imaging device (MRI), measured at approximately 1.5 to 3 Teslas. However, the TMS field is focal (beneath the coil), whereas the MRI field is large and fills the room housing the MRI device.

One hypothesis on how TMS works is that the stimulation of discrete cortical regions alters pathologic activity within a network of gray matter brain regions, specifically those involved in mood regulation and connected to the targeted cortical sites.2 Functional imaging studies support this hypothesis by showing TMS can change activity in brain regions remote from the site of stimulation.3,4

TMS has many molecular effects comparable to electroconvulsive therapy (ECT), including increased monoamine turnover and normalization of the hypothalamic pituitary axis.5 Additionally, in one neuroimaging study of depressed patients, a prefrontal serotonin deficiency at baseline normalized after treatment with TMS.

High-frequency stimulation is thought to excite the targeted neurons and is typically used to activate the left prefrontal cortex. Low-frequency stimulation appears to inhibit cortical activity and is usually directed at the right prefrontal cortex.

Consistent with this hypothesis, a review examined 66 studies in depressed patients who were treated with TMS targeting the dorsolateral prefrontal cortex. It found that high-frequency TMS generally increased regional cerebral blood flow, whereas low-frequency TMS generally decreased regional cerebral blood flow, which is reduced in a depressed brain.6

Indications

TMS is indicated for patients with unipolar major depression who have failed at least 1 antidepressant medication. In addition, TMS is indicated for patients who responded to a prior course of TMS.7

Use of TMS for treatment-resistant or refractory depression is consistent with treatment guidelines from the American Psychiatric Association, Canadian Network for Mood and Anxiety Treatments, and the Royal Australian and New Zealand College of Psychiatrists.

Patient Assessment

When conducting a patient assessment for TMS, the purpose of the evaluation is to confirm the primary diagnosis of treatment-resistant depression and determine whether the TMS intervention can be used safely. The assessment includes examinations of psychiatric history, general medical history, physical health, and mental status with emphasis upon depressive symptoms. This should emphasize risk factors for seizures and preexisting neurologic disease, such as epilepsy, intracranial masses, and vascular abnormalities.

Contraindications

TMS is contraindicated in patients with: increased risks for seizures, implanted metallic hardware (aneurysm clips, bullet fragments, etc), cochlear implants,implanted electrical devices (pacemakers, intracardiac lines, medication pumps, etc), and unstable general medical disorders. See the Sidebar for a 12-item questionnaire for TMS candidates.

Efficacy

Multiple reviews have found consistent evidence that TMS provides a clinically relevant benefit to patients with treatment-resistant depression. In patients with acute major depression who have not responded to at least 1 antidepressant medication, numerous meta-analyses of randomized trials have found that TMS is superior to placebo treatment.8-11 It is not known if maintenance treatment with TMS for unipolar major depression is beneficial.

A meta-analysis of 34 randomized trials compared TMS with placebo treatment in 1383 patients with treatment-resistant major depression. It found that improvement was greater with active treatment.12 Add-on treatment with TMS was efficacious in patients who had not responded to an adequate antidepressant therapy. Response (for example, the reduction of baseline symptoms 50%) occurred in more patients who received active (47%) versus placebo (22%) TMS.12

TMS is less effective than ECT; however, TMS does not require general anesthesia, and it can be done in an outpatient setting. Unlike with ECT, patients with major depression do not experience impaired cognition with TMS.

Predictors of Response

No consistent predictors have been identified in meta-analyses. A 1-year, prospective observational study of 120 patients who responded or remitted with acute TMS found that the durability of response to TMS was not associated with age, sex, severity of depressive symptoms prior to TMS, nor the number of failed antidepressant trials prior to TMS.13

For treatment of major depression, TMS is less efficacious than ECT. Follow-up studies of patients with major depression who were treated acutely with TMS in randomized trials indicate that the short-term benefits of TMS are stable.14 With regard to longer-term benefits of TMS, prospective, observational studies lasting at least 6 months suggest that in patients with major depression who improve with acute TMS, relapse occurs in about 35%.15

For patients with unipolar major depression who improve with a course of TMS and subsequently deteriorate or relapse, reintroduction of TMS using the same stimulation parameters may be helpful.16 It is not known if maintenance treatment with TMS for unipolar major depression is beneficial, as few randomized trials using standard protocols have been conducted. However, in several small, observational studies of patients, the results suggest that maintenance TMS may, perhaps, be beneficial.7

Safety and Adverse Effects

TMS is generally safe and well-tolerated. As an example, a randomized trial of 301 patients found that study discontinuation due to adverse effects was comparable for active and placebo TMS (5% and 3%, respectively).17

The most serious adverse effect of TMS is a generalized tonic-clonic seizure. However, the risk of seizure appears to be comparable to that for antidepressant medications.Seizures probably occur in less than 0.1 to 0.5% of patients when safety guidelines are followed regarding patient selection and stimulation parameters. Seizures that have occurred were self-limited, required no medications, and did not recur.18 Factors that increase the risk of seizures can be found in the Table.

Other side effects include hypomania and mania, described in randomized trials,17 as well as case reports of patients with major depression (both unipolar and bipolar) who were treated with TMS.19,20

However, the clinical significance is not known, because patients with bipolar major depression can switch to mood-elevated states in the absence of an antidepressant treatment. Treatment of unipolar major depression with TMS does not appear to increase suicidal ideation or behavior.21

Common Side Effects of TMS

Headache and scalp pain: A review of randomized trials in patients with major depression found that the incidence of headache with active treatment and placebo treatment was 28% and 16%, respectively. The incidence of scalp pain with active and placebo treatment was 39% and 15%, respectively. No migraine headaches have been reported. Headache and scalp pain may be more pronounced when higher stimulation frequencies and intensities are used. Topical lidocaine may reduce scalp pain. Reducing stimulation intensity can decrease scalp discomfort, but this can also reduce efficacy of treatment. For sensitive patients, the dose of TMS can be titrated up during the first week. Headache and scalp pain generally resolve over the first 2 weeks, although some patients may require an analgesic, such as acetaminophen or ibuprofen.22

Transient (<4 hours) increase in auditory threshold: This is caused by repeated clicks that are produced as current passes through the stimulating magnetic coil and mechanically deforms the coil. Hearing loss is prevented with foam earplugs or noise protection ear coverings.

Vasovagal syncope: Management generally consists of reassurance.

Special Populations

Elderly: For elderly patients with major depression, TMS can be beneficial if the stimulation intensity is sufficient.17 Prefrontal atrophy in older patients can increase the distance between the coil and cortex to the point that lower-intensity stimulation, which typically penetrates to a depth of 2 to 3 cm, does not affect cortical activity. Increasing the intensity above the motor threshold can overcome the added distance.5

Poststroke depression: Depression frequently occurs after stroke, and TMS may help these patients.

Pregnancy and postpartum depression: For these patients with major depression, observational studies suggest that TMS may possibly be safe and effective. It appears unlikely that the fetus is directly affected by TMS because magnetic fields rapidly attenuate with distance.23

Concluding Thoughts

TMS is an exciting and promisingtherapythat can provide real and lastingrelieffor patients suffering from treatment-resistant depression.Conducted in an out-patient setting, TMS isa noninvasive procedure that isgenerally safe and well-tolerated. This providespatients withthe flexibility to seek treatmentin a way that does not disrupttheirdaily lives.TMS has an equallypromising future, with studies exploringitsexpandedapplications, as well as its use asanongoingmaintenance treatment.

Dr Ramanujam is a psychiatrist and Regional Medical Director at Community Psychiatry + MindPath Care Centers.

References

1. Carpenter LL, Janicak PG, Aaronson ST, et al. Transcranial magnetic stimulation (TMS) for major depression: a multisite, naturalistic, observational study of acute treatment outcomes in clinical practice. Depress Anxiety. 2012;29(7):587-596.

2. Baeken C, De Raedt R. Neurobiological mechanisms of repetitive transcranial magnetic stimulation on the underlying neurocircuitry in unipolar depression. Dialogues Clin Neurosci. 2011;13(1):139-145.

3. Kito S, Fujita K, Koga Y.Regional cerebral blood flow changes after low-frequency transcranial magnetic stimulation of the right dorsolateral prefrontal cortex in treatment-resistant depression. Neuropsychobiology. 2008;58(1):29-36.

4. Fitzgerald PB, Sritharan A, Daskalakis ZJ, et al. A functional magnetic resonance imaging study of the effects of low frequency right prefrontal transcranial magnetic stimulation in depression. J Clin Psychopharmacol. 2007;27(5):488.

5. George MS, Post RM. Daily left prefrontal repetitive transcranial magnetic stimulation for acute treatment of medication-resistant depression. Am J Psychiatry. 2011;168(4):356-364.

6. Noda Y, Silverstein WK, Barr MS, et al. Neurobiological mechanisms of repetitive transcranial magnetic stimulation of the dorsolateral prefrontal cortex in depression: a systematic review. Psychol Med. 2015;45(16):3411-3432.

7. Perera T, George MS, Grammer G, et al. The Clinical TMS Society consensus review and treatment recommendations for TMS therapy for major depressive disorder. Brain Stimul. 2016;9(3):336-346.

8. Schutter DJ. Quantitative review of the efficacy of slow-frequency magnetic brain stimulation in major depressive disorder. Psychol Med. 2010;40(11):1789.

9. Berlim MT, Van den Eynde F, Jeff Daskalakis Z. Clinically meaningful efficacy and acceptability of low-frequency repetitive transcranial magnetic stimulation (rTMS) for treating primary major depression: a meta-analysis of randomized, double-blind and sham-controlled trials. Neuropsychopharmacology. 2013;38(4):543.

10. Berlim MT, Van den Eynde F, Daskalakis ZJ. A systematic review and meta-analysis on the efficacy and acceptability of bilateral repetitive transcranial magnetic stimulation (rTMS) for treating major depression. Psychol Med. 2013;43(11):2245.

11. Allan CL, Herrmann LL, Ebmeier KP. Transcranial magnetic stimulation in the management of mood disorders. Neuropsychobiology. 2011;64(3):163-9.

12. Janicak PG, Dokucu ME. Transcranial magnetic stimulation for the treatment of major depression. Neuropsychiatr Dis Treat. 2015;11:1549-1560.

13. Schutter DJ.Antidepressant efficacy of high-frequency transcranial magnetic stimulation over the left dorsolateral prefrontal cortex in double-blind sham-controlled designs: a meta-analysis. Psychol Med. 2009;39(1):65.

14. Kedzior KK, Reitz SK, Azorina V, Loo C. Durability of the antidepressant effect of the high-frequency repetitive transcranial magnetic stimulation (rTMS) in the absence of maintenance treatment in major depression: a systematic review and meta-analysis of 16 double-blind, randomized, sham-controlled trials. Depress Anxiety. 2015;32(3):193.

15. Avery DH, Holtzheimer PE, Fawaz W, et al. A controlled study of repetitive transcranial magnetic stimulation in medication-resistant major depression. Biol Psychiatry. 2006;59(2):187-194.

16. Liu B, Zhang Y, Zhang L, Li L. Repetitive transcranial magnetic stimulation as an augmentative strategy for treatment-resistant depression, a meta-analysis of randomized, double-blind and sham-controlled study. BMC Psychiatry. 2014;14:342.

17. Xia G, Gajwani P, Muzina DJ, et al. Treatment-emergent mania in unipolar and bipolar depression: focus on repetitive transcranial magnetic stimulation. Int J Neuropsychopharmacol. 2008;11(1):119-130.

18. Stultz DJ, Osburn S, Burns T, et al. Transcranial Magnetic Stimulation (TMS) safety with respect to seizures: a literature teview. Neuropsychiatr Dis Treat. 2020;16:2989-3000.

19. Dolberg OT, Schreiber S, Grunhaus L. Transcranial magnetic stimulation-induced switch into mania: a report of two cases. Biol Psychiatry. 2001;49(5):468-70.

20. Garcia-Toro M. Acute manic symptomatology during repetitive transcranial magnetic stimulation in a patient with bipolar depression. Br J Psychiatry. 1999;175:491.

21. Abdelnaim MA, Langguth B, Deppe M, et al. Anti-suicidal efficacy of repetitive transcranial magnetic stimulation in depressive patients: a retrospective analysis of a large sample. Front Psychiatry. 2020;10:929.

22. O'Reardon JP, Solvason HB, Janicak PG, et al. Efficacy and safety of transcranial magnetic stimulation in the acute treatment of major depression: a multisite randomized controlled trial. Biol Psychiatry. 2007;62(11):1208-1216.

23. Rossi S, Hallett M, Rossini PM, et al. Safety, ethical considerations, and application guidelines for the use of transcranial magnetic stimulation in clinical practice and research. Clin Neurophysiol. 2009;120(12):2008-2039.

24. Rossi S, Hallett M, Rossini PM, Pascual-Leone A. Screening questionnaire TMS: an update. Clin Neurophysiol. 2011;122:1686.

See the rest here:

Examining the Benefits of TMS - Psychiatric Times

MINNEAPOLIS--(BUSINESS WIRE)--Advanced Brain + Body Clinic (AB+BC) is a new interventional psychiatric clinic offering ketamine and esketamine (Spravato) therapy, Transcranial Magnetic Stimulation (TMS), and integrative medicine. After opening just four months ago in Minnetonka, MN, Advanced Brain + Body Clinic is already set to double in size, expanding to a second office this month to accommodate the high demand for holistic psychiatric care and hard to find treatment options.

Ketamine, Spravato and TMS offer unique mechanisms of action to treat depression, anxiety, PTSD and suicidal thoughts, said Dr. Brian Johns, Co-Owner of AB+BC. These cutting-edge therapeutics are very well tolerated and highly effective. They should be available to everyone in need, especially considering the worsening mental health crisis of isolation and anxiety during the ongoing pandemic.

Dr. Johns attributes the high demand for AB+BCs services to the clinics commitment to work with most insurance providers. While many other clinics charge patients directly for their ketamine, esketamine, and TMS treatments, AB+BCs goal is to make mental healthcare affordable and available to all.

Ketamine is just one of the many tools that AB+BC uses to help patients suffering with treatment resistant depression (TRD), PTSD and anxiety. Studies show that at least 30% of people with depression have TRD, which is defined by failing two antidepressant medications at adequate dosage and duration. And, once a patient has tried a fourth antidepressant without relief, they only have a 5% chance of success on their 5th antidepressant. Luckily, with the help of TRD specialists, patients have new options with much higher success rate:

Having struggled trying medication after medication, its no surprise that many patients with TRD, PTSD and anxiety are ready to try something new, said Dr. BethAnn Frazier. This is where AB+BC can help. Not only do we offer these innovative treatment methods, but our team of mental health professionals takes a holistic approach to health and wellness, and offers psychiatric medication management.

Dr. Johns and Dr. Frazier use genetic testing and laboratory blood analysis to tailor each patients treatment regimen to maximize overall brain and body health. By understanding a patients hormones, inflammation markers, minerals and more, the team at AB+BC can optimize each patients response to their treatment.

Advanced Brain + Body Clinic opened its second office yesterday at Ridgedale Office Center, 13911 Ridgedale Dr., Ste. 110, Minnetonka, MN. Virtual and in-office appointments can be scheduled today by calling 612-682-4912 or emailing office@advancedbrainbody.com.

Learn more: https://advancedbrainbody.com/

See the original post here:

New Ketamine, TMS and Integrative Medicine Clinic Announces Rapid Expansion Within 4 Months of Opening - Business Wire

BURLINGTON, Mass. and JERUSALEM, Aug. 17, 2021 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (BrainsWay or the Company), a global leader in advanced noninvasive neurostimulation treatments for mental health disorders, today announced that it will host a key opinion leader (KOL) webinar on its Deep TMS therapy for treating mental health disorders on Tuesday, August 31, 2021, at 11am Eastern Time.

The webinar will feature a presentation by KOL Kimberly Cress, M.D., of Greenbrook TMS NeuroHealth Centers, who will discuss the current treatment landscape and unmet medical need in treating patients with obsessive-compulsive disorder (OCD) and how the BrainsWay Deep TMS therapy fits into the treatment paradigm. Dr. Cress will be available to answer questions following the formal presentations.

BrainsWay's Chief Medical Officer, Dr. Aron Tendler, will also participate and share some of the robust body of clinical evidence generated to date with Deep TMS. Deep TMS is a noninvasive neurostimulation treatment that produces significant results by directly stimulating deeper and broader areas of the brain. It is a well-tolerated and effective treatment for multiple mental health disorders, including major depressive disorder, OCD, and smoking addiction.

To register for the webinar, please click here.

Dr. Kimberly Cress joined Greenbrook TMS in November 2018 as Regional Medical Director of the Texas region. She also served as President of the Clinical TMS Society (CTMSS) from 2020 to 2021 and is a member of the CTMSS Education and Insurance Committees. Dr. Cress received her medical degree from the University of Texas Health Science Center, San Antonio, and completed her psychiatric residency at the Baylor College of Medicine in Houston. Dr. Cress has treated patients with TMS therapy since April 2010 and completed Harvard Medical Schools Intensive Course in Transcranial Magnetic Stimulation and Transcranial Direct Current Stimulation, along with completing courses at Duke University in Transcranial Magnetic Stimulation. Dr. Cress says she was drawn to TMS Therapy as a modality because, after finding patients were still struggling with depression and anxiety symptoms despite numerous medication trials and/or therapies, she wanted to help patients regain the quality of life they deserved without unwanted systemic side effects.

About BrainsWayBrainsWay is a global leader in advanced noninvasive neurostimulation treatments for mental health disorders. The Company is boldly advancing neuroscience with its proprietary Deep Transcranial Magnetic Stimulation (Deep TMS) platform technology to improve health and transform lives. BrainsWay is the first and only TMS company to obtain three FDA-cleared indications backed by pivotal studies demonstrating clinically proven efficacy. Current indications include major depressive disorder, obsessive-compulsive disorder, and smoking addiction. The Company is dedicated to leading through superior science and building on its unparalleled body of clinical evidence. Additional clinical trials of Deep TMS in various psychiatric, neurological, and addiction disorders are underway. Founded in 2003, with offices in Burlington, MA and Jerusalem, Israel, BrainsWay is committed to increasing global awareness and broad access to Deep TMS. For the latest news and information about BrainsWay, please visit http://www.brainsway.com.

Forward Looking Statements

This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements may be preceded by the words intends, may, will, plans, expects, anticipates, projects, predicts, estimates, aims, believes, hopes, potential or similar words. These forward-looking statements and their implications are based on the current expectations of the management of the Company only and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. The following factors, among others, could cause actual results to differ materially from those described in the forward-looking statements: inadequacy of financial resources to meet future capital requirements; changes in technology and market requirements; delays or obstacles in launching and/or successfully completing planned studies and clinical trials; failure to obtain approvals by regulatory agencies on the Companys anticipated timeframe, or at all; inability to retain or attract key employees whose knowledge is essential to the development of Deep TMS products; unforeseen difficulties with Deep TMS products and processes, and/or inability to develop necessary enhancements; unexpected costs related to Deep TMS products; failure to obtain and maintain adequate protection of the Companys intellectual property, including intellectual property licensed to the Company; the potential for product liability; changes in legislation and applicable rules and regulations; unfavorable market perception and acceptance of Deep TMS technology; inadequate or delays in reimbursement from third-party payers, including insurance companies and Medicare; inability to commercialize Deep TMS, including internationally, by the Company or through third-party distributors; product development by competitors; inability to timely develop and introduce new technologies, products and applications, and the effect of the global COVID-19 health pandemic on our business and continued uncertainty and market impact relating thereto.

Any forward-looking statement in this press release speaks only as of the date of this press release. The Company undertakes no obligation to publicly update or review any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by any applicable securities laws. More detailed information about the risks and uncertainties affecting the Company is contained under the heading Risk Factors in the Companys filings with the U.S. Securities and Exchange Commission, including the Company's Annual Report on Form 20-F. Investors and security holders are urged to read these documents free of charge on the SECs web site at http://www.sec.gov.

Contacts:

BrainsWay:Scott Areglado SVP and Chief Financial Officer617-771-2287SAreglado@brainsway.com

Investors:Bob YedidLifeSci Advisors646-597-6989Bob@LifeSciAdvisors.com

Follow this link:

BrainsWay Hosting Key Opinion Leader Webinar on its Deep TMS Therapy for Treating Mental Health Disorders - GlobeNewswire

BURLINGTON, Mass. and JERUSALEM, Aug. 17, 2021 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (BrainsWay” or the Company”), a global leader in advanced noninvasive neurostimulation treatments for mental health disorders, today announced that it will host a key opinion leader (KOL) webinar on its Deep TMS therapy for treating mental health disorders on Tuesday, August 31, 2021, at 11am Eastern Time.

The webinar will feature a presentation by KOL Kimberly Cress, M.D., of Greenbrook TMS NeuroHealth Centers, who will discuss the current treatment landscape and unmet medical need in treating patients with obsessive-compulsive disorder (OCD) and how the BrainsWay Deep TMS therapy fits into the treatment paradigm. Dr. Cress will be available to answer questions following the formal presentations.

BrainsWay's Chief Medical Officer, Dr. Aron Tendler, will also participate and share some of the robust body of clinical evidence generated to date with Deep TMS. Deep TMS is a noninvasive neurostimulation treatment that produces significant results by directly stimulating deeper and broader areas of the brain. It is a well-tolerated and effective treatment for multiple mental health disorders, including major depressive disorder, OCD, and smoking addiction.

To register for the webinar, please click here.

Dr. Kimberly Cress joined Greenbrook TMS in November 2018 as Regional Medical Director of the Texas region. She also served as President of the Clinical TMS Society (CTMSS) from 2020 to 2021 and is a member of the CTMSS Education and Insurance Committees. Dr. Cress received her medical degree from the University of Texas Health Science Center, San Antonio, and completed her psychiatric residency at the Baylor College of Medicine in Houston. Dr. Cress has treated patients with TMS therapy since April 2010 and completed Harvard Medical School’s Intensive Course in Transcranial Magnetic Stimulation and Transcranial Direct Current Stimulation, along with completing courses at Duke University in Transcranial Magnetic Stimulation. Dr. Cress says she was drawn to TMS Therapy as a modality because, after finding patients were still struggling with depression and anxiety symptoms despite numerous medication trials and/or therapies, she wanted to help patients regain the quality of life they deserved without unwanted systemic side effects.

About BrainsWay BrainsWay is a global leader in advanced noninvasive neurostimulation treatments for mental health disorders. The Company is boldly advancing neuroscience with its proprietary Deep Transcranial Magnetic Stimulation (Deep TMS) platform technology to improve health and transform lives. BrainsWay is the first and only TMS company to obtain three FDA-cleared indications backed by pivotal studies demonstrating clinically proven efficacy. Current indications include major depressive disorder, obsessive-compulsive disorder, and smoking addiction. The Company is dedicated to leading through superior science and building on its unparalleled body of clinical evidence. Additional clinical trials of Deep TMS in various psychiatric, neurological, and addiction disorders are underway. Founded in 2003, with offices in Burlington, MA and Jerusalem, Israel, BrainsWay is committed to increasing global awareness and broad access to Deep TMS. For the latest news and information about BrainsWay, please visit http://www.brainsway.com.

Forward Looking Statements

This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements may be preceded by the words intends,” may,” will,” plans,” expects,” anticipates,” projects,” predicts,” estimates,” aims,” believes,” hopes,” potential” or similar words. These forward-looking statements and their implications are based on the current expectations of the management of the Company only and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. The following factors, among others, could cause actual results to differ materially from those described in the forward-looking statements: inadequacy of financial resources to meet future capital requirements; changes in technology and market requirements; delays or obstacles in launching and/or successfully completing planned studies and clinical trials; failure to obtain approvals by regulatory agencies on the Company’s anticipated timeframe, or at all; inability to retain or attract key employees whose knowledge is essential to the development of Deep TMS products; unforeseen difficulties with Deep TMS products and processes, and/or inability to develop necessary enhancements; unexpected costs related to Deep TMS products; failure to obtain and maintain adequate protection of the Company’s intellectual property, including intellectual property licensed to the Company; the potential for product liability; changes in legislation and applicable rules and regulations; unfavorable market perception and acceptance of Deep TMS technology; inadequate or delays in reimbursement from third-party payers, including insurance companies and Medicare; inability to commercialize Deep TMS, including internationally, by the Company or through third-party distributors; product development by competitors; inability to timely develop and introduce new technologies, products and applications, and the effect of the global COVID-19 health pandemic on our business and continued uncertainty and market impact relating thereto.

Any forward-looking statement in this press release speaks only as of the date of this press release. The Company undertakes no obligation to publicly update or review any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by any applicable securities laws. More detailed information about the risks and uncertainties affecting the Company is contained under the heading Risk Factors” in the Company’s filings with the U.S. Securities and Exchange Commission, including the Company's Annual Report on Form 20-F. Investors and security holders are urged to read these documents free of charge on the SEC’s web site at http://www.sec.gov.

Contacts:

BrainsWay: Scott Areglado SVP and Chief Financial Officer 617-771-2287 SAreglado@brainsway.com

Investors: Bob Yedid LifeSci Advisors 646-597-6989 Bob@LifeSciAdvisors.com

Read more from the original source:

BrainsWay Hosting Key Opinion Leader Webinar on its Deep TMS(TM) Therapy for Treating Mental Health Disorders - Stockhouse

ON THE U.S. EXIT. MONI: AN UPDATE FROM A STORY FROM A COUPLE WEEKS AGO. TWOEN M ARE ARRESTED IN CONNECTION WITH A BURGLARY AT TM S DIESEL. LAST MONTH, THEY WEER CAUTGH CUTTING THE LOCKS TO THE BUILDING AND LEAVING WITH CASH AND PART

2 men arrested in connection with break-in at Weare business

Updated: 5:47 PM EDT Aug 14, 2021

Two men have been arrested in connection to a break in that occurred at a business in Weare last month.According to Weare Police, Zachary Wildman of Concord and Jeremy Fortin of Manchester were arrested in connection with the burglary at TMS Diesel.Last month, security cameras captured two people cutting the locks to the building and leaving with cash and parts. Police said the investigation continues and ask that anyone with information contact them.

Two men have been arrested in connection to a break in that occurred at a business in Weare last month.

According to Weare Police, Zachary Wildman of Concord and Jeremy Fortin of Manchester were arrested in connection with the burglary at TMS Diesel.

Last month, security cameras captured two people cutting the locks to the building and leaving with cash and parts.

Police said the investigation continues and ask that anyone with information contact them.

Originally posted here:

2 men arrested in connection with break-in at Weare business - WMUR Manchester

Louisianas two predominant oil and gas plays, Tuscaloosa Marine Shale and Haynesville Shale, have taken starkly divergent paths over the past decade. While poor market conditions have made the TMS too risky for most drillers, Haynesville rig counts are on the rise due to burgeoning liquefied natural gas exports.

Patrick Courreges, communications director at the Louisiana Department of Natural Resources, says recent DNR data tells the tale. Theres currently only one active drilling permit in the TMS and dozens in the Haynesville play. Were seeing about 30-odd rigs split between Haynesville Shale and the Cotton Valley formation, he says. That has been fairly steady.

The shale play boom began with little fanfare about a decade ago. For the first time, advances in horizontal drilling and hydraulic fracturing enabled oil producers to access what had before been commercially unavailable. The relatively high oil and natural gas prices at the time provided the incentive for experimentation and risk-taking, and U.S. production began to surge.

The massive TMS, which covers 8 million acres in Louisiana and Mississippi, has long tantalized oil companies and economic development officials, but idiosyncratic extraction challenges and the 2014 price plunge have kept it from realizing its economic potential.

Meanwhile, theres an entirely different reality underway in northwest Louisiana. Haynesville Shale has hitched its wagon to the growing LNG export business and the dry gas it offers has made it very attractive.

You just dont get dry holes (in Haynesville), Courreges says. They know how to drill it, know how to fracture it, and how to get the best out of it. Louisiana is now at 3 trillion feet a year in gas production, with the bulk of that coming from Haynesville. Read the full story from the latest edition of Business Report here.

More:

Louisianas two major oil and gas plays offer study in contrasts - Greater Baton Rouge Business Report

Most people behave in one or more ways that others may consider peculiar, and I am no exception. I want my clothes to match, from shoes to eyeglasses and everything in between (including underwear a challenge when packing for a trip). If visitors use my kitchen, theyre asked to put things back exactly where they were found. In arranging my furniture, countertops and wall-hangings, I strive for symmetry. And I label packaged foods with their expiration dates and place them in my pantry in date order.

I know Im not the only one with quirks like these that others may consider so OCD, a reference to obsessive-compulsive disorder. But the clinical syndrome, in which people have unbidden recurring thoughts that lead to repetitive habits, is far more than a collection of quirky behaviours. Rather, it is a highly distressing and chronic neuropsychological condition that can trigger serious anxiety and make it difficult to function well in school, at work or at home.

For someone with OCD, certain circumstances or actions that most people would consider harmless, like touching a doorknob, are believed to have potentially dire consequences that require extreme corrective responses, if not total avoidance. A person may so fear germs, for example, that shaking someones hand can compel them to wash their own hand 10, 20 or even 30 times to be sure its clean.

For many, the COVID-19 pandemic only made things worse. Past research has found a potential correlation between traumatic experience and increased risk of developing OCD, as well as worsening symptoms. A person with OCD who already believes dangerous germs lurk everywhere would, understandably, have become paralysed with anxiety by the spread of the novel coronavirus. And indeed, a Danish study published in October found that the early months of the pandemic resulted in increased anxiety and other symptoms in both newly diagnosed and previously treated OCD patients ages 7-21.

How serious is OCD?

The disorder often runs in families, and different members can be affected to varying degrees. Symptoms of the condition often begin in childhood or adolescence, afflicting an estimated 1 per cent to 2 per cent of young people and rising to about 1 in 40 adults. About half are seriously impaired by the disorder, 35 per cent moderately affected and 15 per cent mildly affected.

It is not hard to see how the disorder can be so disruptive. A person with OCD who is concerned that they may fail to lock the door, for example, may feel compelled to unlock and relock it over and over. Or they may become unduly stressed and anticipate disaster if a strict routine, like switching a light on and off 10 times, is not followed before leaving a room. Some people with OCD are plagued by taboo thoughts about sex or religion or by a fear of harming themselves or others.

Comedian Howie Mandel, now 65, told MedPage Today in June that he has suffered from OCD since childhood, but wasnt officially diagnosed until many years later after spending most of his life living in a nightmare and struggling with an obsession about germs. He has been working to help counter the stigma of mental illness and increase public understanding of OCD in hopes that greater awareness of the disorder will foster early recognition and treatment to avert its life-impairing effects.

How is OCD treated?

Until the mid-1980s, OCD was considered untreatable, said Caleb W. Lack, a professor of psychology at the University of Central Oklahoma. But now, he said, there are three evidence-based therapies that may be effective, even for the most severely afflicted: psychotherapy, pharmacology and a technique called transcranial magnetic stimulation, which sends magnetic pulses to specific areas of the brain.

Most patients are initially offered a form of cognitive behavioral therapy, called exposure and response prevention. Starting with something least likely to elicit anxiety for example, showing a used tissue to people with an obsessive fear of contamination patients are encouraged to resist a compulsive response, like repeated hand-washing. Patients are taught to engage in self-talk, exploring the often irrational thoughts that are going through their heads, until their anxiety level declines.

When they see that no illness has resulted from viewing the tissue, the therapy can progress to a more provocative exposure, like touching the tissue, and so forth, until they overcome their unrealistic fear of contamination. For especially fearful patients, this therapeutic approach is often combined with a medication that counters depression or anxiety.

One silver lining of the pandemic is that it may have allowed more people to get treated remotely through online health services. With telemedicine, were able to do very effective treatment for patients, no matter where they may live in relation to the therapist, Lack said. Without ever leaving central Oklahoma, I can see patients in 20 states. Patients dont have to be within a 30-mile radius of the therapist. Telemedicine is a real game-changer for people who wont or cant leave home.

For highly impaired OCD patients for whom nothing else has worked, the latest option is transcranial magnetic stimulation, or TMS, a noninvasive technique that stimulates nerve cells in the brain and helps to redirect neural circuits that are involved in obsessive thoughts and compulsions.

Its as if the brain is stuck in a rut, and TMS helps the brain circuitry get on a different path, Lack explained. As with exposure and response prevention, he said, TMS uses provocative exposures, but combines them with magnetic stimulation to help the brain more effectively resist the urge to respond.

In a study of 167 severely affected OCD patients at 22 clinical sites published in May, 58% remained significantly improved after an average of 20 sessions with TMS. The Food and Drug Administration has approved the technique for treating OCD, though many insurance companies are not yet offering coverage.

Where can I get help?

Bradley Riemann, a psychologist at Rogers Behavioral Health System in Oconomowoc, Wisconsin, said his organization, which has 20 locations in nine states, relies on treatment teams that include psychologists, psychiatrists, nurses and social workers to provide both outpatient and inpatient treatment for OCD patients as young as age 6. Too often, Riemann said, parents inadvertently reinforce the problem by clearing a path so that their child can avoid their obsessive fear and resulting compulsive response. For example, they might routinely open doors for a child fearful of contamination.

The nonprofit International OCD Foundation, based in Boston, can help patients and families find therapists and support groups for those struggling with the condition. A message can be left at 617-973-5801.

This article originally appeared in The New York Times.

Read this article:

Living with OCD in a pandemic - The Indian Express